PROGRESSIVE'S EVENING STROLL   DATE: 11 August, 2026

Market Snapshot:

After an initial drop in early trade, the Index moved sideways for the rest of the session and ended at 24,471.70, down 112.10 points. The Pharma sector outperformed with gains of over 1%, while the Capital Market Index continued to show positive momentum. On the other hand, FMCG and Realty underperformed. Broader markets were mixed, with Midcaps ending in the red and Smallcaps rising 0.22%.

HOW THE DAY TRENDED

INDICES

Index	Close	Points	%Chg.
Sensex	78154.25	(388.19)	**(0.49)**
Nifty50	24471.70	(112.10)	**(0.46)**
Nifty Midcap 100	63843.85	(11.85)	**(0.02)**
Nifty Small Cap 100	19857.15	43.20	**0.22**

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY PHARMA	26750.45	270.90	**1.02**
NIFTY CAPITAL MKT	5337.55	42.05	**0.79**
NIFTY REALTY	889.10	(8.85)	**(0.99)**
NIFTY FMCG	48787.85	(575.75)	**(1.17)**

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
DR REDDY	1205.00	**3.99**	TATA CONSUMER	1078.00	**(2.77)**
ETERNAL	318.00	**2.50**	MAX HEALTHCARE	1040.00	**(2.71)**
TCS	2445.70	**0.82**	NESTLE IND	1493.20	**(2.32)**
TITAN	5128.00	**0.75**	ULTRATECH	11780.00	**(2.14)**

INDICES LEVELS FOR August 12, 2026

Nifty (future)	
Resistance	24615
Support	24455

Bank Nifty (future)	
Resistance	57740
Support	57365



PROGRESSIVE'S EVENING STROLL **DATE: 11 August, 2026**

KEY TAKEAWAYS OF THE DAY

- **Lupin announces the approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the US:**

The company has received approval from the USFDA for Sodium Zirconium Cyclosilicate for oral suspension, 5g/packet and 10g/packet. The drug is bioequivalent to the reference listed drug (RLD), Lokelma for oral suspension, manufactured by AstraZeneca Pharmaceuticals LP, and is indicated for the treatment of hyperkalemia in adults. Sodium Zirconium Cyclosilicate for oral suspension had estimated annual sales of USD568mn in the US, according to IQVIA MAT data for June 2026.

- **Texmaco Rail executed MoU with Belgium's Signalling Company:**

The company has executed a Memorandum of Understanding (MoU) with The Signalling Company NV, Belgium (TSC) to establish a strategic collaboration for an ETCS solution, including but not limited to the purpose of the contemplated Kavach development for the Indian market.

- **JSW Energy adds 1,166MW renewable capacity since April, total capacity hits 14.9GW:**

The company has announced the addition of 1,166MW of renewable capacity since April 2026. With this addition, it has already surpassed 94% of its total organic capacity addition achieved in FY26. Further, following the recent completion of the acquisition of Maruti Clean Coal and Power, JSW Energy's total installed capacity has increased to 14,920MW.

- **Zen Technologies bags Rs295cr order from Defence Ministry for simulators:**

Zen Technologies secured a Rs295cr order from the Ministry of Defence for simulators, enhancing its order pipeline, which totals Rs1,239.02cr. The revenue outlook is positive as new products and Air Force training offerings are in development, despite a decline in profits this quarter.

- **BEL secured Rs541cr in new defense orders:**

BEL has secured additional orders worth Rs541cr since July 31. Major orders received include communication equipment, electro-optics, ammunition fuzes, Chemical, Biological, Radiological and Nuclear (CBRN) systems, spares and services.

Source: Media Reports

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

<u>Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:</u>

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai—400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500.

Grievance Officer:
Email: grievancecell@progressiveshares.com